X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Elder Pharma Fact Sheet, Elder Pharma Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Elder Pharma Fact Sheet   (ELDER)

Here is the latest financial fact sheet of Elder Pharma. For more details, see the Elder Pharma quarterly results and Elder Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

ELDER PHARMA Price History

Price Rs 38.0
Mkt Cap Rs m 781
Vol '000 20.5
P/E X -0.2
P/CF X 2.6
EPS (TTM) Rs -220.6
% ch % 5.0
No. of shares m 20.54
% ch week % 5.0
% ch 1-mth % 27.1
% ch 12-mth % -64.5
52 week H/L Rs 118.8/20.4
(As on Sep 12, 2016 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

ELDER PHARMA Financials

No. of Mths
Year Ending
12
Mar-11
*
12
Mar-12
*
12
Mar-13
*
15
Jun-13
*
12
Jun-14
*
5-Yr Chart
Click to enlarge
ELDER PHARMA EQUITY SHARE DATA
High Rs440435416416380 
Low Rs321298202202188 
Sales per share (Unadj.) Rs470.0649.8799.3799.3491.2 
Earnings per share (Unadj.) Rs31.335.240.140.1-3.2 
Diluted earnings per shareRs31.335.240.140.1-3.2 
Cash flow per share (Unadj.) Rs45.351.761.661.614.4 
Dividends per share (Unadj.) Rs3.003.00000 
Adj. dividends per shareRs3.003.000.000.000.00 
Dividend yield (eoy) %0.80.8000 
Book value per share (Unadj.) Rs307.0341.1374.5374.5376.5 
Adj. book value per shareRs307.0341.1374.5374.5376.5 
Shares outstanding (eoy) m20.5420.5420.5420.5420.54 
Bonus/Rights/Conversions  PP---- 
Price / Sales ratio x0.80.60.40.40.6 
Avg P/E ratio x12.210.47.77.7-89.3 
P/CF ratio (eoy) x8.47.15.05.019.7 
Price / Book Value ratio x1.21.10.80.80.8 
Dividend payout %9.68.5000 
Avg Mkt Cap Rs m7,8157,5286,3486,3485,833 
No. of employees `0003.63.5NANANA 
Total wages/salary Rs m1,2261,7992,3312,3312,179 
Avg. sales/employee Rs Th2,674.63,773.8NMNMNM 
Avg. wages/employee Rs Th339.7508.6NMNMNM 
Avg. net profit/employee Rs Th178.0204.3NMNMNM 
ELDER PHARMA INCOME DATA
Net Sales Rs m9,65313,34816,41716,41710,089 
Other income Rs m87265327327257 
Total revenues Rs m9,73913,61316,74416,74410,346 
Gross profit Rs m1,3311,9902,7342,734-792 
Depreciation Rs m287340441441361 
Interest Rs m2811,0161,5481,5482,756 
Profit before tax Rs m8499001,0711,071-3,653 
Minority Interest Rs m70000 
Prior Period Items Rs m80000 
Extraordinary Inc (Exp) Rs m-4515-28-283,713 
Tax Rs m177193219219125 
Profit after tax Rs m642723824824-65 
Gross profit margin %13.814.916.716.7-7.8 
Effective tax rate %20.821.420.520.5-3.4 
Net profit margin %6.75.45.05.0-0.6 
ELDER PHARMA BALANCE SHEET DATA
Current assets Rs m8,2788,7828,7918,7919,240 
Current liabilities Rs m5,8036,9579,9989,9989,998 
Net working cap to sales %25.613.7-7.4-7.4-7.5 
Current ratio x1.41.30.90.90.9 
Inventory Days Days9180545446 
Debtors Days Days10793898960 
Net fixed assets Rs m7,4258,9739,6319,63110,124 
Share capital Rs m206206206206206 
"Free" reserves Rs m5,4365,7906,1216,1215,582 
Net worth Rs m6,3077,0067,6937,6937,734 
Long term debt Rs m5,0955,8257,0397,0394,889 
Total assets Rs m17,41519,99824,92524,92522,882 
Interest coverage x4.01.91.71.7-0.3 
Debt to equity ratio x0.80.80.90.90.6 
Sales to assets ratio x0.60.70.70.70.4 
Return on assets %5.38.79.59.511.8 
Return on equity %10.210.310.710.7-0.8 
Return on capital %9.615.017.617.622.3 
Exports to sales %2.42.11.91.93.0 
Imports to sales %3.62.31.81.80.4 
Exports (fob) Rs m228280318318307 
Imports (cif) Rs m35130629129143 
Fx inflow Rs m228280318318307 
Fx outflow Rs m388334361361125 
Net fx Rs m-160-54-43-43181 
ELDER PHARMA CASH FLOW
From Operations Rs m 657 148 194 166 11,754 
From Investments Rs m -1,507 -1,711 -632 -632 -561 
From Financial Activity Rs m 2,734 433 -67 -39 -6,762 
Net Cashflow Rs m 1,885 -1,131 -506 -506 4,432 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 39.6%
Foreign collaborators 0.0%
Indian inst/Mut Fund 7.5%
FIIs 16.8%
ADR/GDR 0.0%
Free float 36.1%
Shareholders 16,479
Pledged promoter(s) holding 77.6%
 

Company Information

REGD OFF Elder House, Plot No. C-9, Dalia Indl. Estate, Off Veera Desai Road, Mumbai-53
E-MAIL s.p.date@elderindia.com WEB www.elderindia.com
TELEPHONE (022) 2673 0058 FAX (022) 2673 0051
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Intime Spectrum, C-13, Pannalal Silk Mills Compd., LBS Marg, Mumbai - 78
AUDITOR S. S. Khandelwal & Co.
CHM: J. Saxena COMP SEC: S. P. Date YEAR OF INC: 1900 BSE CODE: 532322 FV (Rs): 10 DIV YIELD (%): -

More Pharmaceuticals Company Fact Sheets:   DR. REDDYS LAB  CADILA HEALTHCARE  WYETH LTD  GLENMARK PHARMA  BIOCON LTD  

Compare ELDER PHARMA With:   DR. REDDYS LAB  CADILA HEALTHCARE  WYETH LTD  GLENMARK PHARMA  BIOCON LTD  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Flat; Capital Goods & Pharma Stocks Witness Selling Pressure(11:30 am)

After touching record highs in the morning trade, Indian markets witnessed some selling momentum to trade flat. Losses are largely seen in capital goods stocks and pharma stocks.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

More Views on News

Most Popular

Ride the Bull Wave with These Perfect Proxies to India's Growth Story(The 5 Minute Wrapup)

Jul 15, 2017

The secret of spotting multibaggers before they become a hit.

The Real Returns from Real Estate Have Been Very Low(Vivek Kaul's Diary)

Jul 17, 2017

Real estate prices across India have barely gone anywhere over the last four years. Prices have fallen in many cities over the last one-year, new data from the National Housing Bank suggests.

The New Pharma Rally Starts NOW(Daily Profit Hunter)

Jul 12, 2017

The most hated sector is offering the best trading opportunity. Are you ready?

All You Need To Know To e-File Your Income Tax Returns(Outside View)

Jul 12, 2017

The Income Tax return filing deadline is drawing near; if you have not already filed your taxes, here's how to do it.

Sold Your Immoveable Property? Here Are The Tax Implications...(Outside View)

Jul 19, 2017

When you're selling an immoveable property, it becomes imperative to recognise the intricate tax implications.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ELDER PHARMA

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS